

29 July 2025

Business progress update on Exclusive Distribution Agreement with Zimmer Biomet

Highlights

- On 16 July 2024, Osteopore signed an Exclusive Distribution Agreement with Zimmer Pte Ltd, the Singapore-based subsidiary of Zimmer Biomet Holdings, Inc., (Zimmer Biomet, NYSE and SIX:ZBH) to distribute craniofacial products in Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC) including Australia, and New Zealand.
- Zimmer Biomet has since commenced sales of Osteopore products in Europe, Australia, and Hong Kong.
- In the first 12 months of the partnership (2024 H2 to 2025 H1)¹, the number of implants sold from these countries grew three-fold as compared to the 12 months prior (2023 H2 to 2024 H1).

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX: OSX; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to provide a business progress update on the Exclusive Distribution Agreement (**Agreement**) with global medical technology leader Zimmer Biomet (NYSE and SIX:ZBH).

¹ Revenue in H1 2025 is unreported as of this announcement. Osteopore expects to place its Q2 Quarterly report by the end of July 2025, in line with reporting requirements by ASX.



Osteopore struck an Exclusive Distribution Agreement with Zimmer Biomet on 16 July 2024².

In the first 12 months of the partnership months between 2024 H2 and 2025 H1, Zimmer Biomet launched Osteopore products in Europe, Australia, and Hong Kong.

The number of Osteopore craniofacial products sold in these regions and countries **grew three-fold** compared to the previous 12-month period (2023 H2 to 2024 H1) prior to Zimmer Biomet's appointment.

Commenting on the initial performance with Zimmer Biomet, CEO Dr Yujing Lim, said:

"We are delighted with the strong and encouraging performance of Osteopore products in their first 12 months with Zimmer Biomet.

"Importantly, we have also demonstrated resilience in our manufacturing capacity and ability to scale.

"Looking ahead, with the recent European approval of our custom-made cranioplasty implants, while it may take time for the adoption of innovative medical devices like ours, we expect stronger traction gradually from existing markets and will work with Zimmer Biomet to launch new markets", said Dr. Lim.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr. Yujing Lim
Chief Executive Officer
Osteopore Limited
E: lim_yujing@osteopore.com

Mark Leong
Executive Chairman
Osteopore Limited
E: mark_leong@osteopore.com

² ASX announcement "Osteopore strikes Exclusive Distribution with Zimmer Biomet", 16 July 2024.



About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.

